Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002313607 | SCV000848738 | likely benign | Inborn genetic diseases | 2017-01-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000959822 | SCV001106756 | benign | Rubinstein-Taybi syndrome | 2025-01-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001613445 | SCV001837079 | benign | not provided | 2020-02-19 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001613445 | SCV005217363 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003938072 | SCV004756419 | likely benign | CREBBP-related disorder | 2019-09-17 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |